arGEN-X advances a third therapeutic antibody program into preclinical development: http://t.co/hBB8aUOQ
posted 2 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
TiGenix (NYSE EURONEXT: TIG) announces that the US Patent & Trademark Office has granted a new patent for ChondroMimetic™.
This new patent (US 7,780,994) entitled "Composite biomaterials comprising calcium phosphate materials, collagen and glycosaminoglycans" describes and claims the composition of and methods to produce a composite material comprising a triple coprecipitate of collagen, one or more glycosaminoglycans (GAG) and calcium phosphate. This patent forms the core protection of our ChondroMimetic product family.
The patent application was filed in the name of Cambridge Enterprise and exclusively licensed to TiGenix Ltd. (the former Orthomimetics Ltd). The patent was already granted in the United Kingdom, Singapore and China. Additional patent applications are pending in other jurisdictions around the world.
“I’m extremely pleased with the issuance of this important US patent on the eve of the launch of ChondroMimetic. We expect further geographical expansion of ChondroMimetic’s intellectual property protection in the near future.” says Andrew Lynn, founder of Orthomimetics and co-inventor on the patent, now Chief Business Officer at TiGenix.
Source: Tigenix
Tags: legal
Bookmark this:
